VEGFA and hepatocellular carcinoma: Atezolizumab, an anti-programmed death-ligand (PD-L1) monoclonal antibody, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, have been used in combination for unresectable HCC.